诺和诺德13亿美元收购项目案,是兵不厌诈还是商业欺诈

第一财经
Sep 02

2023年10月11日,诺和诺德以最高达13亿美元的价格收购了亨利医药(KBP Biosciences)小分子非甾体盐皮质激素受体拮抗剂Ocedurenone。2024年6月,诺和诺德公布Ocedurenone治疗慢性肾脏病患者高血压的三期临床数据,认为中期分析中研究没有达到主要终点,要在2024年二季度确认8亿美元损失,随后诺和诺德终止了该药三期临床试验。2025年初,诺和诺德以转让方亨利医药及...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10